MAP2K7 and melanoma: The NRAS mutated subtype, which accounts for a quarter of all melanoma cases, lacks such a targeted approach but ongoing clinical trials are assessing the effects of combined MEK and CDK4/6 inhibitors (NCT01781572; NCT02065063).